Conecte-se

Bibliografias temáticas / Cystic fibrosis Gene therapy / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Cystic fibrosis Gene therapy.

Artigos de revistas sobre o tema "Cystic fibrosis Gene therapy"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 11 de fevereiro de 2022

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Cystic fibrosis Gene therapy".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Griesenbach, Uta, Jane C. Davies e Eric Alton. "Cystic fibrosis gene therapy". Current Opinion in Pulmonary Medicine 22, n.º 6 (novembro de 2016): 602–9. http://dx.doi.org/10.1097/mcp.0000000000000327.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Colledge, W. H., e M. J. Evans. "Cystic fibrosis gene therapy". British Medical Bulletin 51, n.º 1 (janeiro de 1995): 82–90. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072955.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Colledge, William H. "Cystic fibrosis gene therapy". Current Opinion in Genetics & Development 4, n.º 3 (junho de 1994): 466–71. http://dx.doi.org/10.1016/0959-437x(94)90037-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Prickett, Michelle, e Manu Jain. "Gene therapy in cystic fibrosis". Translational Research 161, n.º 4 (abril de 2013): 255–64. http://dx.doi.org/10.1016/j.trsl.2012.12.001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Colledge, WH. "Gene therapy for cystic fibrosis". Lancet 349, n.º 9060 (abril de 1997): 1249. http://dx.doi.org/10.1016/s0140-6736(97)26017-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Dodge, J. A. "Gene therapy for cystic fibrosis". Nature Medicine 1, n.º 3 (março de 1995): 182. http://dx.doi.org/10.1038/nm0395-182a.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Armstrong, D. K., S. Cunningham, J. C. Davies e E. W. F. Alton. "Gene therapy in cystic fibrosis". Archives of Disease in Childhood 99, n.º 5 (24 de janeiro de 2014): 465–68. http://dx.doi.org/10.1136/archdischild-2012-302158.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Wagner, MD, PhD, John A., e Phyllis Gardner, MD. "TOWARD CYSTIC FIBROSIS GENE THERAPY". Annual Review of Medicine 48, n.º 1 (fevereiro de 1997): 203–16. http://dx.doi.org/10.1146/annurev.med.48.1.203.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Flotte, Terence R., e Beth L. Laube. "Gene Therapy in Cystic Fibrosis". Chest 120, n.º 3 (setembro de 2001): 124S—131S. http://dx.doi.org/10.1378/chest.120.3_suppl.124s.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Alton, Eric, Stephen Smith e Duncan Geddes. "Gene therapy for cystic fibrosis". Lancet 349, n.º 9060 (abril de 1997): 1249–50. http://dx.doi.org/10.1016/s0140-6736(05)62441-5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Janet E Larson, Y., Susan L. Morrow e J. Craig Cohen. "Gene therapy for cystic fibrosis". Lancet 349, n.º 9060 (abril de 1997): 1250. http://dx.doi.org/10.1016/s0140-6736(05)62442-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Turner, Gillian. "Gene therapy for cystic fibrosis". Lancet 349, n.º 9060 (abril de 1997): 1250–51. http://dx.doi.org/10.1016/s0140-6736(05)62443-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Boyd, A. Christopher. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 11, n.º 1 (janeiro de 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.1.1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Boyd, A. Christopher. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 11, n.º 2 (fevereiro de 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.2.1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Conese, Massimo, Sante Di Gioia e Stefano Castellani. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 18, n.º 8 (agosto de 2008): 929–43. http://dx.doi.org/10.1517/13543776.18.8.929.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Davies, Jane C., Duncan M. Geddes e Eric W. F. W. Alton. "Gene therapy for cystic fibrosis". Journal of Gene Medicine 3, n.º 5 (2001): 409–17. http://dx.doi.org/10.1002/jgm.200.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Bellon, G. "Cystic fibrosis (CF) gene therapy". Pediatric Pulmonology 23, S16 (abril de 1997): 278–79. http://dx.doi.org/10.1002/ppul.19502308144.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Johnson, Larry G. "Gene Therapy for Cystic Fibrosis". Chest 107, n.º 2 (fevereiro de 1995): 77S—83S. http://dx.doi.org/10.1378/chest.107.2_supplement.77s.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Rosenfeld, Melissa A., e Francis S. Collins. "Gene Therapy for Cystic Fibrosis". Chest 109, n.º 1 (janeiro de 1996): 241–52. http://dx.doi.org/10.1378/chest.109.1.241.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Coutelle, C., N. Caplen, S. Hart, C. Huxley e R. Williamson. "Gene therapy for cystic fibrosis." Archives of Disease in Childhood 68, n.º 4 (1 de abril de 1993): 437–40. http://dx.doi.org/10.1136/adc.68.4.437.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Kitson, Chris, e Eric Alton. "Gene therapy for cystic fibrosis". Expert Opinion on Investigational Drugs 9, n.º 7 (julho de 2000): 1523–35. http://dx.doi.org/10.1517/13543784.9.7.1523.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Davies, J. C., e E. W. F. W. Alton. "Gene Therapy for Cystic Fibrosis". Proceedings of the American Thoracic Society 7, n.º 6 (28 de outubro de 2010): 408–14. http://dx.doi.org/10.1513/pats.201004-029aw.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Luder, Elisabeth. "Gene Therapy for Cystic Fibrosis". Topics in Clinical Nutrition 14, n.º 4 (setembro de 1999): 22–30. http://dx.doi.org/10.1097/00008486-199909000-00004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Mueller, Christian, e Terence R. Flotte. "Gene Therapy for Cystic Fibrosis". Clinical Reviews in Allergy & Immunology 35, n.º 3 (4 de julho de 2008): 164–78. http://dx.doi.org/10.1007/s12016-008-8080-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Alton, E. W. F. W. "Gene therapy for cystic fibrosis". Journal of Inherited Metabolic Disease 18, n.º 4 (1995): 501–7. http://dx.doi.org/10.1007/bf00710061.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Geddes, D. "Gene therapy for cystic fibrosis". Netherlands Journal of Medicine 46, n.º 6 (junho de 1995): 306–12. http://dx.doi.org/10.1016/0300-2977(95)00024-h.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Coutelle, Charles. "Gene therapy approaches for cystic fibrosis". Biologicals 23, n.º 1 (março de 1995): 21–25. http://dx.doi.org/10.1016/1045-1056(95)90006-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Brown, Matt. "Gene therapy trials for cystic fibrosis". Drug Discovery Today 7, n.º 15 (agosto de 2002): 788–89. http://dx.doi.org/10.1016/s1359-6446(02)02393-0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Higgins, Christopher F., Stephen C. Hyde e Deborah R. Gill. "Towards Gene Therapy for Cystic Fibrosis". Biochemical Society Transactions 27, n.º 5 (1 de outubro de 1999): A137. http://dx.doi.org/10.1042/bst027a137a.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

ALTON, E. W. F. W. "Towards Gene Therapy For Cystic Fibrosis*". Journal of Pharmacy and Pharmacology 47, n.º 5 (maio de 1995): 351–54. http://dx.doi.org/10.1111/j.2042-7158.1995.tb05809.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Ezzell, C. "Gene Therapy for Cystic Fibrosis Patients". Science News 142, n.º 24 (12 de dezembro de 1992): 405. http://dx.doi.org/10.2307/4017870.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

O'Neal, WK, e AL Beaudet. "Somatic gene therapy for cystic fibrosis". Human Molecular Genetics 3, suppl_1 (1 de setembro de 1994): 1497–502. http://dx.doi.org/10.1093/hmg/3.suppl_1.1497.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Griesenbach, Uta, Duncan M. Geddes e Eric W. F. W. Alton. "Advances in cystic fibrosis gene therapy". Current Opinion in Pulmonary Medicine 10, n.º 6 (novembro de 2004): 542–46. http://dx.doi.org/10.1097/01.mcp.0000142102.91202.04.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Griesenbach, U., e E. W. F. W. Alton. "Moving forward: cystic fibrosis gene therapy". Human Molecular Genetics 22, R1 (4 de agosto de 2013): R52—R58. http://dx.doi.org/10.1093/hmg/ddt372.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Parsons, DW. "Airway gene therapy and cystic fibrosis". Journal of Paediatrics and Child Health 41, n.º 3 (março de 2005): 94–96. http://dx.doi.org/10.1111/j.1440-1754.2005.00556.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Wilson, James. "Cystic Fibrosis: Strategies for Gene Therapy". Seminars in Respiratory and Critical Care Medicine 15, n.º 05 (setembro de 1994): 439–45. http://dx.doi.org/10.1055/s-2007-1006389.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Drittanti, L., MV Masciovecchio, J. Gabbarini e M. Vega. "Cystic fibrosis: gene therapy or preventive gene transfer?" Gene Therapy 4, n.º 10 (outubro de 1997): 1001–3. http://dx.doi.org/10.1038/sj.gt.3300526.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Kutsev, S. I., V. L. Izhevskaya e E. I. Kondratyeva. "Targeted therapy for cystic fibrosis". PULMONOLOGIYA 31, n.º 2 (11 de abril de 2021): 226–36. http://dx.doi.org/10.18093/0869-0189-2021-31-2-226-236.

Texto completo da fonte

Resumo:

The basic therapy of cystic fibrosis is currently aimed at slowing down the pathological processes associated with a decrease in the CFTR protein activity (cystic fibrosis transmembrane conductance regulator) in the gastrointestinal tract and the respiratory system. The pancreatic insufficiency is well compensated by replacement therapy with microsphere enzyme preparations and a high-calorie diet rich in proteins and fat. Chronic treatment of cystic fibrosis-related lung disease aims to improve the clearance of the bronchial tree, suppressing chronic bacterial infection and local chronic inflammation. However, no therapy was available to correct the defect in the gene or its product until 2012.The aim was to analyze literature on CFTR modulators, including their efficacy and safety, and assess the potential for developing new modulators to treat cystic fibrosis.Materials. The review included literature data (45 publications) on the use of CFTR modulators and international websites’ data.Results. Since the discovery of the CFTR gene in 1989, more than 2000 mutations or variants of the CFTR gene (hereinafter referred to as genetic variants) have been described. They interfere with the synthesis of the CFTR protein, its transport to the apical membrane of the cell, or disrupt its function as a channel for chloride anions. Although it is currently not possible to completely replace the mutant gene with a normal copy, small molecules have been identified that can modify the mutant CFTR protein and amend its function. The potential therapeutic measures are determined by class of the mutation. In clinical practice, pharmacological modeling of ion transport is currently possible only with the use of CFTR modulators: correctors and potentiators. The review defines these groups of drugs and describes 4 licensed CFTR modulators, including molecules of ivacaftor, lumacaftor, tezacaftor, elexacaftor. The data on the promising emerging next generation modulators and the prospects for the personalized selection of drugs using the assays on intestinal organoids are presented.

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

LEE, Tim W. R., David A. MATTHEWS e G. Eric BLAIR. "Novel molecular approaches to cystic fibrosis gene therapy". Biochemical Journal 387, n.º 1 (22 de março de 2005): 1–15. http://dx.doi.org/10.1042/bj20041923.

Texto completo da fonte

Resumo:

Gene therapy holds promise for the treatment of a range of inherited diseases, such as cystic fibrosis. However, efficient delivery and expression of the therapeutic transgene at levels sufficient to result in phenotypic correction of cystic fibrosis pulmonary disease has proved elusive. There are many reasons for this lack of progress, both macroscopically in terms of airway defence mechanisms and at the molecular level with regard to effective cDNA delivery. This review of approaches to cystic fibrosis gene therapy covers these areas in detail and highlights recent progress in the field. For gene therapy to be effective in patients with cystic fibrosis, the cDNA encoding the cystic fibrosis transmembrane conductance regulator protein must be delivered effectively to the nucleus of the epithelial cells lining the bronchial tree within the lungs. Expression of the transgene must be maintained at adequate levels for the lifetime of the patient, either by repeat dosage of the vector or by targeting airway stem cells. Clinical trials of gene therapy for cystic fibrosis have demonstrated proof of principle, but gene expression has been limited to 30 days at best. Results suggest that viral vectors such as adenovirus and adeno-associated virus are unsuited to repeat dosing, as the immune response reduces the effectiveness of each subsequent dose. Nonviral approaches, such as cationic liposomes, appear more suited to repeat dosing, but have been less effective. Current work regarding non-viral gene delivery is now focused on understanding the mechanisms involved in cell entry, endosomal escape and nuclear import of the transgene. There is now increasing evidence to suggest that additional ligands that facilitate endosomal escape or contain a nuclear localization signal may enhance liposome-mediated gene delivery. Much progress in this area has been informed by advances in our understanding of the mechanisms by which viruses deliver their genomes to the nuclei of host cells.

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Castellani, Stefano, e Massimo Conese. "Lentiviral Vectors and Cystic Fibrosis Gene Therapy". Viruses 2, n.º 2 (29 de janeiro de 2010): 395–412. http://dx.doi.org/10.3390/v2020395.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

&NA;. "Is gene therapy for cystic fibrosis realistic?" Inpharma Weekly &NA;, n.º 1137 (maio de 1998): 6. http://dx.doi.org/10.2165/00128413-199811370-00008.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

DAGANI, RON. "Big step toward cystic fibrosis gene therapy". Chemical & Engineering News 70, n.º 3 (20 de janeiro de 1992): 6. http://dx.doi.org/10.1021/cen-v070n003.p006.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Davies, Jane C. "Gene and cell therapy for cystic fibrosis". Paediatric Respiratory Reviews 7 (janeiro de 2006): S163—S165. http://dx.doi.org/10.1016/j.prrv.2006.04.214.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Tizzano, Eduardo F., e Manuel Buchwald. "Cystic fibrosis: Beyond the gene to therapy". Journal of Pediatrics 120, n.º 3 (março de 1992): 337–49. http://dx.doi.org/10.1016/s0022-3476(05)80895-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Jaffe, A., A. Bush, D. M. Geddes e E. W. F. W. Alton. "Prospects for gene therapy in cystic fibrosis". Archives of Disease in Childhood 80, n.º 3 (1 de março de 1999): 286–89. http://dx.doi.org/10.1136/adc.80.3.286.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Alton, Eric WFW, e Duncan Geddes. "Gene Therapy: The Case for Cystic Fibrosis". Journal of the Royal Society of Medicine 90, n.º 31_suppl (dezembro de 1997): 43–46. http://dx.doi.org/10.1177/014107689709031s09.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Caplen, Natasha J. "Cystic fibrosis gene therapy trials and tribulations". Trends in Molecular Medicine 7, n.º 11 (novembro de 2001): 488. http://dx.doi.org/10.1016/s1471-4914(01)02168-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Davies, Jane C., Duncan M. Geddes e Eric W. F. W. Alton. "Prospects for gene therapy for cystic fibrosis". Molecular Medicine Today 4, n.º 7 (julho de 1998): 292–99. http://dx.doi.org/10.1016/s1357-4310(98)01265-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Fox, Jeffrey L. "NIHRAC okays gene therapy for cystic fibrosis". Nature Biotechnology 11, n.º 1 (janeiro de 1993): 29. http://dx.doi.org/10.1038/nbt0193-28b.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Griesenbach, U., S. Ferrari, D. M. Geddes e E. W. F. W. Alton. "Gene Therapy Progress and Prospects: Cystic fibrosis". Gene Therapy 9, n.º 20 (outubro de 2002): 1344–50. http://dx.doi.org/10.1038/sj.gt.3301791.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!